The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.8M data for 1.2M Compounds and 9.2K Targets. Of those, 1,346K data for 622K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

41 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Computer-aided selection of potential antihypertensive compounds with dual mechanism of action.EBI
Institute Of Biomedical Chemistry Of Russian Academy Of Medical Sciences
Potent and selective non-peptidic inhibitors of endothelin-converting enzyme-1 with sustained duration of action.EBI
Novartis Institute For Biomedical Research
Protease inhibitors: current status and future prospects.EBI
University Of Queensland
Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents.EBI
F. Hoffmann-La Roche
New alpha-thiol dipeptide dual inhibitors of angiotensin-I converting enzyme and neutral endopeptidase EC 3.4.24.11.EBI
Ciba-Geigy
N-Phosphonomethyl dipeptides and their phosphonate prodrugs, a new generation of neutral endopeptidase (NEP, EC 3.4.24.11) inhibitors.EBI
Ciba-Geigy
Design and synthesis of an orally active macrocyclic neutral endopeptidase 24.11 inhibitor.EBI
Ciba-Geigy
Enkephalinase inhibitors. 1. 2,4-Dibenzylglutaric acid derivatives.EBI
Ciba-Geigy
Synthesis and biological evaluation of phosphonamidate peptide inhibitors of enkephalinase and angiotensin-converting enzyme.EBI
TBA
New bidentates as full inhibitors of enkephalin-degrading enzymes: synthesis and analgesic properties.EBI
TBA
 
Design and synthesis of phosphinic acids that triply inhibit endothelin converting enzyme, angiotensin converting enzyme and neutral endopeptidase 24.11EBI
TBA
 
Highly potent and selective inhibitors of endothelin converting enzymeEBI
TBA
 
Potent inhibitors of neutral endopeptidase. 2-Biphenyl- methylglutaric acid amide derivativesEBI
TBA
 
4-Substituted proline derivatives that inhibit angiotensin converting enzyme and neutral endopeptidase 24.11.EBI
TBA
 
Mercaptoacyl dipeptides as dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase. Preliminary structure-activity studiesEBI
TBA
 
Aminophosphonate endothelin converting enzyme inhibitors: potency-enhancing and selectivity-improving modifications of phosphoramidonEBI
TBA
 
The synthesis of aminobenzazepinones as anti-phenylalanine dipeptide mimics and their use in nep inhibitionEBI
TBA
 
Design and synthesis of a new class of conformationally constrained inhibitors to probe the active sites of thermolysine and neutral endopeptidase 24.11EBI
TBA
 
Synthesis of constrained thiorphan analogs as inhibitors of neutral endopeptidaseEBI
TBA
 
α-Mercaptoacyl dipeptides that inhibit angiotensin converting enzyme and neutral endopeptidase 24.11EBI
TBA
 
Non-peptidic inhibitors of neutral endopeptidase 24.11 2. Design and pharmacology of orally active phosphonate prodrugsEBI
TBA
 
Non-peptidic inhibitors of neutral endopeptidase 24.11 1. Discovery and optimization of potencyEBI
TBA
 
The effect of heteroatom substitution on a series of phosphonate inhibitors of neutral endopeptidase 24.11EBI
TBA
 
Gem-cycloalkyl substituted thiol inhibitors of neutral endopeptidase 24.11. Synthesis via nucleophilic opening of 2,2-spiro-β-lactonesEBI
TBA
Novel selective inhibitors of neutral endopeptidase for the treatment of female sexual arousal disorder.EBI
Pfizer
Novel selective inhibitors of neutral endopeptidase for the treatment of female sexual arousal disorder. Synthesis and activity of functionalized glutaramides.EBI
Pfizer
N-formyl hydroxylamine containing dipeptides: generation of a new class of vasopeptidase inhibitors.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Molecular Basis for Omapatrilat and Sampatrilat Binding to Neprilysin-Implications for Dual Inhibitor Design with Angiotensin-Converting Enzyme.EBI
University Of Bath
Vasopeptidase inhibitors: incorporation of geminal and spirocyclic substituted azepinones in mercaptoacyl dipeptides.EBI
The Bristol-Myers Squibb Pharmaceutical Research Institute
Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.EBI
Shionogi
Dual metalloprotease inhibitors. 6. Incorporation of bicyclic and substituted monocyclic azepinones as dipeptide surrogates in angiotensin-converting enzyme/neutral endopeptidase inhibitors.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Synthesis and analgesic effects of N-[3-[(hydroxyamino) carbonyl]-1-oxo-2(R)-benzylpropyl]-L-isoleucyl-L-leucine, a new potent inhibitor of multiple neurotensin/neuromedin N degrading enzymes.EBI
Ccipe-Faculté
Application of a conformationally restricted Phe-Leu dipeptide mimetic to the design of a combined inhibitor of angiotensin I-converting enzyme and neutral endopeptidase 24.11.EBI
Marion Merrell Dow Research Institute
Heterocyclic lactam derivatives as dual angiotensin converting enzyme and neutral endopeptidase 24.11 inhibitors.EBI
Ciba-Geigy
Dicarboxylic acid dipeptide neutral endopeptidase inhibitors.EBI
Ciba-Geigy
1H NMR configurational correlation for retro-inverso dipeptides: application to the determination of the absolute configuration of"enkephalinase" inhibitors. Relationships between stereochemistry and enzyme recognition.EBI
TBA
A novel class of enkephalinase inhibitors containing a C-terminal sulfo group.EBI
Dainippon Pharmaceutical